<DOC>
	<DOCNO>NCT01211509</DOCNO>
	<brief_summary>Chronic rejection ( Bronchiolitis Obliterans syndrome-BOS ) major cause mortality morbidity lung transplantation . Because montelukast show efficacy similar disease ( Obliterative Bronchiolitis bone marrow transplantation ) , investigator would like test montelukast indeed slow progression chronic rejection lung transplantation .</brief_summary>
	<brief_title>Montelukast Bronchiolitis Obliterans Syndrome</brief_title>
	<detailed_description>- Prospective , interventional , randomize , double-blind , placebo-controlled trial . - Clinical setting ( tertiary University Hospital ) . - Investigator-driven , pharmaceutical sponsor . - Lung transplant recipient . - Add-on study-drug ( placebo montelukast ) 'standard care ' - 1:1 inclusion ratio ( placebo : montelukast ) . - Randomisation diagnosis chronic rejection inform consent .</detailed_description>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Diagnosis fBOS Signed informed consent Age least 18 year old moment transplantation Able take oral medication Retransplantation Previous organ transplantation Multi organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>montelukast</keyword>
	<keyword>cysteinyl leukotriene</keyword>
	<keyword>lung transplantation</keyword>
	<keyword>bronchiolitis obliterans syndrome</keyword>
</DOC>